South Korea · Health Care · KRW (Millions) · Annual
Key financials
KRW|Millions
ROE
-57.68%
2025 (actual)
ROA
-29.75%
2025 (actual)
Gross Margin
53.1%
2025 (actual)
Net Margin
-161.65%
2025 (actual)
Total Assets
₩456,637.11M
2025 (actual)
Net Income
-₩138,174.72M
2025 (actual)
Valuation
₩1,503,965.69M
2026 (forecast)
Stock Price
₩61,100
Historical & projected performance
KRW|Millions
Reported figures and Equlion model projections for the next 5 years.
ROE
+94.3 pt
Company
ROA
-44.6 pt
Company
Gross Margin
-6.9 pt
Company
Sector average
Net Margin
-39.3 pt
Company
Total Assets
+98.2%
Company
Sector average
Net Income
-371.8%
Company
Sector average (own scale)
Valuation
+151.6%
Company
Sector average
Stock Price
+151.6%
Company
Sector average
Amounts in KRW (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for L&C BIO Co.,LTD? It covers the balance sheet, income statement, cash flow and Equlion model projections.